{
    "doi": "https://doi.org/10.1182/blood.V120.21.3160.3160",
    "article_title": "Acute Leukemia in Hispanic Americans: Incidence and Incidence Rate Differences by Nativity. ",
    "article_date": "November 16, 2012",
    "session_type": "901. Health Services and Outcomes Research: Poster II",
    "abstract_text": "Abstract 3160 Introduction: Acute leukemias (AL) have a distinct incidence pattern in Hispanics versus Caucasians, with higher rates of B-cell acute lymphoblastic leukemia (ALL) and acute promyelocytic leukemia (APL), and lower rates of non-APL acute myeloid leukemia (AML). Despite the fact that incidence differentials between foreign- and native-born populations can inform the relative contributions of environmental and genetic factors in cancer etiology, no such investigation has been undertaken in Hispanics with AL. Methods: To better understand heritable genetic versus environmental contributors to occurrence patterns, we assessed AL incidence in a large population of California Hispanics according to birthplace. Cancer incidence data were obtained from the California Cancer Registry, part of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Patients were included if they were living in California and diagnosed between 2000\u20132009 with AL. Population estimates were obtained from the 2000 Census Summary Files 3, and estimates by nativity were derived from the 20% Integrated Public-Use Microdata Sample of the censuses. Results: Compared to Caucasians, Hispanics had an increased incidence of B-cell ALL and APL, with incidence rate ratios (IRR) of 2.13 (95% confidence interval [CI] 1.93\u20132.35) and 1.33 (95% CI 1.12\u20131.57), respectively. There was no difference in B-cell ALL incidence by nativity, with an IRR for foreign- to native-born Hispanics of 1.07 (95% CI 0.85\u20131.34). However, foreign-born Hispanics had a greater incidence of APL than native-born Hispanics (IRR 1.79, 95% CI 1.11\u20132.94). Conclusions: Our findings suggest the increased B-cell ALL incidence for foreign-born Hispanics is influenced by heritable genetic factors. Furthermore, the increased incidence of APL for foreign-born Hispanics may result from environmental exposures currently not described and which require further epidemiologic investigation. Table 1: Age-adjusted incidence rates (per 100,000 person-years) of acute leukemias and incidence rate ratios (IRR) by race/ethnicity among non-Hispanic Whites and Hispanics, and nativity among Hispanics*, 2000\u20132004 and 2000\u20132009  Hematological Malignancy . Race/Ethnicity \u2020 or Nativity . Male . Female . Male and Female . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . B-Cell ALL \u2020  White 478 0.78 (0.71\u20130.85) 1.00 (reference) 365 0.54 (0.48\u20130.60) 1.00 (reference) 843 0.65 (0.61\u20130.70) 1.00 (reference)  Hispanic 542 1.39 (1.26\u20131.54) 1.80 (1.57\u20132.06) 451 1.36 (1.23\u20131.50) 2.53 (2.19\u20132.94) 993 1.39 (1.30\u20131.49) 2.13 (1.93\u20132.35) Non\u2013APL AML \u2020  White 3118 4.87 (4.70\u20135.04) 1.00 (reference) 2480 3.17 (3.04\u20133.30) 1.00 (reference) 5598 3.91 (3.81\u20134.02) 1.00 (reference)  Hispanic 846 3.83 (3.54\u20134.14) 0.79 (0.72\u20130.86) 694 2.63 (2.42\u20132.84) 0.83 (0.76\u20130.91) 1540 3.13 (2.96\u20133.31) 0.80 (0.75\u20130.85) APL \u2020  White 207 0.33 (0.28\u20130.38) 1.00 (reference) 162 0.24 (0.21\u20130.29) 1.00 (reference) 369 0.29 (0.26\u20130.32) 1.00 (reference)  Hispanic 134 0.36 (0.30\u2013.044) 1.11 (0.87\u20131.42) 141 0.40 (0.33\u20130.47) 1.61 (1.26\u20132.06) 275 0.38 (0.33\u20130.43) 1.33 (1.12\u20131.57) B\u2013Cell ALL **  US-Born 91 1.28 (1.00\u20131.63) 1.00 (reference) 69 1.10 (0.83\u20131.42) 1.00 (reference) 160 1.24 (1.04\u20131.48) 1.00 (reference)  Foreign-Born 142 1.33 (1.07\u20131.65) 1.04 (0.75\u20131.45) 114 1.23 (0.99\u20131.50) 1.11 (0.80\u20131.57) 256 1.32 (1.15\u20131.52) 1.07 (0.85\u20131.34) Non\u2013APL AML **  US\u2013Born 169 4.37 (3.66\u20135.18) 1.00 (reference) 147 3.16 (2.65\u20133.73) 1.00 (reference) 316 3.64 (3.22\u20134.10) 1.00 (reference)  Foreign-Born 224 3.95 (3.34\u20134.63) 0.90 (0.71\u20131.15) 189 2.72 (2.31\u20133.17) 0.86 (0.68\u20131.09) 413 3.21 (2.86\u20133.58) 0.88 (0.75\u20131.04) APL **  US\u2013Born 12 ***  ***  21 0.29 (0.17\u20130.47) 1.00 (reference) 33 0.23 (0.15\u2013400.34) 1.00 (reference)  Foreign-Born 40 0.41 (0.27\u20130.59) ***  42 0.42 (0.30\u20130.59) 1.44 (0.78\u20132.72) 82 0.41 (0.32\u20130.53) 1.79 (1.11\u20132.94) Hematological Malignancy . Race/Ethnicity \u2020 or Nativity . Male . Female . Male and Female . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . Cases . Incidence Rate * (95% CI) . IRR (95% CI) . B-Cell ALL \u2020  White 478 0.78 (0.71\u20130.85) 1.00 (reference) 365 0.54 (0.48\u20130.60) 1.00 (reference) 843 0.65 (0.61\u20130.70) 1.00 (reference)  Hispanic 542 1.39 (1.26\u20131.54) 1.80 (1.57\u20132.06) 451 1.36 (1.23\u20131.50) 2.53 (2.19\u20132.94) 993 1.39 (1.30\u20131.49) 2.13 (1.93\u20132.35) Non\u2013APL AML \u2020  White 3118 4.87 (4.70\u20135.04) 1.00 (reference) 2480 3.17 (3.04\u20133.30) 1.00 (reference) 5598 3.91 (3.81\u20134.02) 1.00 (reference)  Hispanic 846 3.83 (3.54\u20134.14) 0.79 (0.72\u20130.86) 694 2.63 (2.42\u20132.84) 0.83 (0.76\u20130.91) 1540 3.13 (2.96\u20133.31) 0.80 (0.75\u20130.85) APL \u2020  White 207 0.33 (0.28\u20130.38) 1.00 (reference) 162 0.24 (0.21\u20130.29) 1.00 (reference) 369 0.29 (0.26\u20130.32) 1.00 (reference)  Hispanic 134 0.36 (0.30\u2013.044) 1.11 (0.87\u20131.42) 141 0.40 (0.33\u20130.47) 1.61 (1.26\u20132.06) 275 0.38 (0.33\u20130.43) 1.33 (1.12\u20131.57) B\u2013Cell ALL **  US-Born 91 1.28 (1.00\u20131.63) 1.00 (reference) 69 1.10 (0.83\u20131.42) 1.00 (reference) 160 1.24 (1.04\u20131.48) 1.00 (reference)  Foreign-Born 142 1.33 (1.07\u20131.65) 1.04 (0.75\u20131.45) 114 1.23 (0.99\u20131.50) 1.11 (0.80\u20131.57) 256 1.32 (1.15\u20131.52) 1.07 (0.85\u20131.34) Non\u2013APL AML **  US\u2013Born 169 4.37 (3.66\u20135.18) 1.00 (reference) 147 3.16 (2.65\u20133.73) 1.00 (reference) 316 3.64 (3.22\u20134.10) 1.00 (reference)  Foreign-Born 224 3.95 (3.34\u20134.63) 0.90 (0.71\u20131.15) 189 2.72 (2.31\u20133.17) 0.86 (0.68\u20131.09) 413 3.21 (2.86\u20133.58) 0.88 (0.75\u20131.04) APL **  US\u2013Born 12 ***  ***  21 0.29 (0.17\u20130.47) 1.00 (reference) 33 0.23 (0.15\u2013400.34) 1.00 (reference)  Foreign-Born 40 0.41 (0.27\u20130.59) ***  42 0.42 (0.30\u20130.59) 1.44 (0.78\u20132.72) 82 0.41 (0.32\u20130.53) 1.79 (1.11\u20132.94) * Standardized to the 2000 US population age standard \u25a1Age-adjusted incidence rates (per 100,000 person-years) of acute leukemias and incidence rate ratios (IRR) by race/ethnicity among non-Hispanic Whites and Hispanics age 3 20 in California, 2000\u20132009 ** Age-adjusted incidence rates (per 100,000 person-years) of hematological malignancies and incidence rate ratios by nativity among Hispanics >/= 20 in California, 2000\u20132004 *** Insufficient case counts to calculate rate View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "burkitt's lymphoma",
        "hispanics or latinos",
        "leukemia, acute",
        "b-cell acute lymphocytic leukemia",
        "cancer",
        "genetic aspects",
        "hematologic neoplasms",
        "acute promyelocytic leukemia",
        "leukemia, b-cell, acute",
        "leukemia, myelocytic, acute"
    ],
    "author_names": [
        "Daniel A Pollyea, MD, MS",
        "Holbrook E Kohrt, MD, PhD",
        "Juan Yang, PhD",
        "Ellen T Chang, Sc., D",
        "Scarlett Lin Gomez, PhD",
        "Christina A Clarke, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Daniel A Pollyea, MD, MS",
            "author_affiliations": [
                "Hematologic Malignancies and Bone Marrow Transplantation, University of Colorado, Aurora, CO, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Holbrook E Kohrt, MD, PhD",
            "author_affiliations": [
                "Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Yang, PhD",
            "author_affiliations": [
                "Cancer Prevention Institute of California and Department of Health Research and Policy, Stanford University, Fremont, CA, USA, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ellen T Chang, Sc., D",
            "author_affiliations": [
                "Cancer Prevention Institute of California, Fremont, CA, USA, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Scarlett Lin Gomez, PhD",
            "author_affiliations": [
                "Cancer Prevention Institute of California and Department of Health Research and Policy, Stanford University, Freemont, CA, USA"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Christina A Clarke, PhD",
            "author_affiliations": [
                "Cancer Prevention Institute of California, Fremont, CA, USA, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-21T09:32:09",
    "is_scraped": "1"
}